EyeYon Medical
Ophthalmic Products for Vision-threatening Conditions
Startup C Health Tech & Life Sciences Est. 2010
Total Raised
$36.14M
C
Last Round
$25M
4 rounds
Investors
12
12 public
Team
5
11-50 employees
Confidence
92/100
News
12
articles
Patents
1
About
EyeYon Medical is a start-up company specializing in developing medical ophthalmic devices for complications resulting from various corneal diseases, including corneal edema. EyeYon Medical has developed exclusive technologies that have proven to have a solution to acute problems in the ophthalmic world. EyeYon Medical's flagship product is an artificial endothelial layer called EndoArt. EndoArt is a synthetic implant attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction. The minimally invasive EndoArt is designed to replace dysfunctional endothelium to cure corneal edema, offering a safe and simple solution that will be available to anyone, anywhere. EyeYon Medical also developed the Hyper CL, an FDA-approved therapeutic contact lens for a variety of corneal conditions that require eye drop treatment.
Classification
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Core Technology
Materials & SubstancesImplants
Target Customer
Healthcare & Life SciencesHealthcarePatientsProviders
Business Model
B2B
Tags
bioconvergencemedical-technologieseye-diseasesmedical-devicesminimally-invasiveophthalmologypatientslensesnon-invasivenon-surgicalclinicshealthcare-providershospitalstreatmentsoptronics
Funding & Events
Mar 2021
C Round $25M
CR-CP Life Science Fund (Lead), Triventures, Quark Venture, Diamond Bio Fund , BPC, Pontifax, Rimonci Capital
Mar 2017
B Round $8M
Rimonci Capital, Gauss Group, Pontifax, Triventures, Diamond Bio Fund
Jan 2010
Seed $488K
Sagam Group, VLX Ventures
Apr 2015
A Round $2.65M
Docor International Management, Office of the Chief Scientist, Pontifax, Triventures
News (12)
Feb 5, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.,...
ExpandPartnersProduct Stage
Feb 22, 2022 · www.prnewswire.com
growth-positive
EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer
Management Changes
Jun 7, 2021 · nocamels.com
growth-positive
Israel's EyeYon Medical Receives CE Mark For Its Synthetic Implant
CustomersInvestment
Apr 7, 2021 · www.prnewswire.com
growth-positive
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China
PartnersInvestment
Mar 15, 2021 · www.calcalistech.com
growth-positive
EyeYon Medical raises $25 million for corneal implants
Investment
Sep 24, 2020 · www.maariv.co.il
growth-positive
מבט לעתיד: המיזם הישראלי שפיתח שתל מלאכותי לעין
Customers
Feb 5, 2020 · www.prnewswire.com
growth-positive
Breakthrough Device Designation Received From the FDA for EndoArt®
Customers
Mar 21, 2017 · www.globes.co.il
growth-positive
Ophthalmic device co EyeYon Medical raises $6.5m
InvestmentExpand
Sep 6, 2016 · blog.optoprep.com
growth-positive
Link: FDA Approves EyeYon Corneal Edema Treatment
Customers
Apr 21, 2015 · en.globes.co.il
growth-positive
Israeli eye treatment co EyeYon Medical raises $3.6m
InvestmentExpand
Feb 25, 2014 · blogs.timesofisrael.com
growth-positive
Trailblazing is Israel's last name
Customers
Aug 1, 2013 · www.israel21c.org
growth-positive
EyeYon's noninvasive answer to a common eye problem
Customers
Details
Product Stage
Released
Employees
11-50
Exact Count
30
District
Center District
Founded
2010
Registrar
514509603
Crunchbase
eyeyon
Locations
5 Golda Meir St., Ness Ziona, Israel
Links
Website
LinkedIn
Twitter
Facebook
Admin
Last Update
Feb 17, 2025
Verified by
Yanina Wainscheinker
Missing
markets, not claimed
Team (5)
Nahum Ferera
Co-founder & CEO
Founder
Arie Marcovich
Co-founder
Founder
Ofer Daphna
Co-founder & Medical Director
Founder
Sharon Bakalash
CMO
Dmitry Dubson
VP R&D
Internal
Created by
Rebecca Mack (rebeccamack26@gmail.com)
Created
2014-07-17T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)